News

The approval for the thrombopoietin (TPO) receptor agonist is for adult patients who are scheduled to go through a medical or dental procedure. The regulator said Doptelet is the

The company reported positive results from phase III Haven 3 study assessing Hemlibra prophylaxis administered every week or every two weeks in people with haemophilia A without factor

Hyperkalemia is a serious condition characterized by high levels of potassium in the blood (greater than 5.0 mEq/L). The risk of hyperkalemia increases significantly for patients with chronic

The newly established Seattle-based company's goal is to support GC Pharma's vaccine development activities. GC Pharma builds a strategic collaboration and partnership with global health organizations IDRI (Infectious

The late-stage trial named SPARTAN was held by the Johnson & Johnson (J&J) subsidiary in nmCRPC patients who had a rapidly increasing PSA while receiving continuous androgen deprivation

The investment has been provided by venture capital firm The Column Group, biotech venture capital company Atlas Venture and EcoR1 Capital, a fundamental biotechnology-focused investment advisory firm. Accent

This approval allows for the marketing of Cabometyx (cabozantinib) in this indication in all 28 member states of the European Union, Norway and Iceland. Ipsen chief commercial officer and

Results showed that adjunctive treatment with LYRICA 14 mg/kg/day resulted in a statistically significant reduction in seizure frequency versus placebo, the primary efficacy endpoint. Treatment with LYRICA at

Aimovig blocks the calcitonin gene-related peptide receptor (CGRP-R), which is considered to play an important role in migraine. The drug’s effectiveness for the preventive treatment of migraine was